dwb2023/gtopdb-target-family-interaction-detail huggingface dataset:
Target family: Nitric oxide synthases (type: enzyme)
Target: Inducible NOS

Ligand: tilarginine (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.070000171661377 pKi
Reference (Journal): Conformationally restricted arginine analogues as inhibitors of human nitric oxide synthase
Published in: Bioorganic and Medicinal Chemistry Letters

Ligand: PIBTU (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity: 7.3 pIC50
Reference (Journal): Potent and selective inhibition of human nitric oxide synthases. Inhibition by non-amino acid isothioureas.
Published in: J Biol Chem

Ligand: NIL (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity: 5.5 pIC50
Reference (Journal): L-N6-(1-iminoethyl)lysine: a selective inhibitor of inducible nitric oxide synthase.
Published in: J Med Chem

Ligand: L-NNA (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.170000076293945 pKi
Reference (Journal): N-Phenylamidines as selective inhibitors of human neuronal nitric oxide synthase: structure-activity studies and demonstration of in vivo activity.
Published in: J Med Chem

Ligand: GW274150 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 7.150000095367432 pIC50
Reference (Journal): 2-aminopyridines as highly selective inducible nitric oxide synthase inhibitors. Differential binding modes dependent on nitrogen substitution.
Published in: J Med Chem

Ligand: aminoguanidine (Metabolite)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity:  -
Reference (Journal): Does nitric oxide mediate autoimmune destruction of beta-cells? Possible therapeutic interventions in IDDM.
Published in: Diabetes

Ligand: 2-amino-4-methylpyridine (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity: 7.4 pIC50
Reference (Journal): 2-Amino-4-methylpyridine as a potent inhibitor of inducible NO synthase activity in vitro and in vivo.
Published in: Br J Pharmacol

Ligand: 1400W (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity: 8.2 pIC50
Reference (Journal): 1400W is a slow, tight binding, and highly selective inhibitor of inducible nitric-oxide synthase in vitro and in vivo.
Published in: J Biol Chem
Target family: Nitric oxide synthases (type: enzyme)
Target: Endothelial NOS

Ligand: tilarginine (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.400000095367432 pKi
Reference (Journal): Conformationally restricted arginine analogues as inhibitors of human nitric oxide synthase
Published in: Bioorganic and Medicinal Chemistry Letters

Ligand: L-NNA (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.519999980926514 pKi
Reference (Journal): N-Phenylamidines as selective inhibitors of human neuronal nitric oxide synthase: structure-activity studies and demonstration of in vivo activity.
Published in: J Med Chem

Ligand: GW274150 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 4.46999979019165 pIC50
Reference (Journal): 2-aminopyridines as highly selective inducible nitric oxide synthase inhibitors. Differential binding modes dependent on nitrogen substitution.
Published in: J Med Chem
Target family: Nitric oxide synthases (type: enzyme)
Target: Neuronal NOS

Ligand: ZZL-7 (Peptide)
Interaction type: None
Action: Binding
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Design of fast-onset antidepressant by dissociating SERT from nNOS in the DRN.
Published in: Science

Ligand: tilarginine (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.079999923706055 pKi
Reference (Journal): Conformationally restricted arginine analogues as inhibitors of human nitric oxide synthase
Published in: Bioorganic and Medicinal Chemistry Letters

Ligand: NANT (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity:  -
Target family: NKF1 family (type: enzyme)
Target: sugen kinase 110

Ligand: compound R-16 [PMID: 21967808] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Improvement in oral bioavailability of 2,4-diaminopyrimidine c-Met inhibitors by incorporation of a 3-amidobenzazepin-2-one group.
Published in: Bioorg Med Chem
Target family: NKF2 family (type: enzyme)
Target: PTEN induced kinase 1

Ligand: MTK458 (Synthetic organic)
Interaction type: Activator
Action: Activation
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Pharmacological PINK1 activation ameliorates Pathology in Parkinson's Disease models.
Published in: bioRxiv
Target family: nmo subfamily (type: enzyme)
Target: nemo like kinase

Ligand: compound 25 [PMID: 17935989] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 5.789999961853027 pIC50
Reference (Journal): Macrocyclic ureas as potent and selective Chk1 inhibitors: an improved synthesis, kinome profiling, structure-activity relationships, and preliminary pharmacokinetics.
Published in: Bioorg Med Chem Lett
Target family: NOD-like receptor family (type: catalytic_receptor)
Target: NLRP1

Ligand: muramyl dipeptide (Natural product)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity:  -
Target family: NOD-like receptor family (type: catalytic_receptor)
Target: NLRP3

Ligand: oridonin (Natural product)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.28000020980835 pKd
Reference (Journal): Oridonin is a covalent NLRP3 inhibitor with strong anti-inflammasome activity.
Published in: Nat Commun

Ligand: oridonin derivative 32 [PMID: 38751194] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.110000133514404 pIC50
Reference (Journal): Hit-to-Lead Optimization of the Natural Product Oridonin as Novel NLRP3 Inflammasome Inhibitors with Potent Anti-Inflammation Activity.
Published in: J Med Chem

Ligand: selnoflast (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6 pIC50
Reference (Patent): Novel sulfonamide carboxamide compounds
Target family: NOD-like receptor family (type: catalytic_receptor)
Target: NLRX1

Ligand: amelenodor (Synthetic organic)
Interaction type: Activator
Action: Activation
Ligand approved: no
Primary target: no
Median affinity: 4.519999980926514 pKd
Reference (Patent): 1,3,5-tris(6-methylpyridin-2-yloxy)benzene derivatives and related compounds as nlrx1 ligands for treating inflammatory diseases
Target family: NOD-like receptor family (type: catalytic_receptor)
Target: nucleotide binding oligomerization domain containing 1

Ligand: meso-DAP (Natural product)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity:  -

Ligand: ML130 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 6.25 pIC50
Reference (Journal): Identification of Inhibitors of NOD1-Induced Nuclear Factor-κB Activation.
Published in: ACS Med Chem Lett
Target family: NOD-like receptor family (type: catalytic_receptor)
Target: nucleotide binding oligomerization domain containing 2

Ligand: ML130 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 4.699999809265137 pIC50
Reference (Journal): Identification of Inhibitors of NOD1-Induced Nuclear Factor-κB Activation.
Published in: ACS Med Chem Lett

Ligand: muramyl dipeptide (Natural product)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity:  -
Target family: Non-enzymatic BRD containing proteins (type: other_protein)
Target: CREB binding protein

Ligand: TTK21 (Synthetic organic)
Interaction type: Activator
Action: Activation
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): A novel activator of CBP/p300 acetyltransferases promotes neurogenesis and extends memory duration in adult mice.
Published in: J Neurosci

Ligand: ischemin (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 4.71999979019165 pKd
Reference (Journal): A small molecule binding to the coactivator CREB-binding protein blocks apoptosis in cardiomyocytes.
Published in: Chem Biol

Ligand: inobrodib (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.770000457763672 pKd
Reference (Journal): Targeting the p300/CBP Axis in Lethal Prostate Cancer.
Published in: Cancer Discov

Ligand: inobrodib (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.849999904632568 pKd
Reference (Journal): Design, Synthesis, and Biological Evaluation of 1-(Indolizin-3-yl)ethan-1-ones as CBP Bromodomain Inhibitors for the Treatment of Prostate Cancer.
Published in: J Med Chem

Ligand: I-CBP112 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 6.849999904632568 pKd
Reference (Webpage): I-CBP112 A CREBBP/EP300-selective chemical probe

Ligand: GNE-049 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.960000038146973 pIC50
Reference (Journal): GNE-781, A Highly Advanced Potent and Selective Bromodomain Inhibitor of Cyclic Adenosine Monophosphate Response Element Binding Protein, Binding Protein (CBP).
Published in: J Med Chem

Ligand: compound 50 [PMID: 24313754] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.199999809265137 pIC50
Reference (Journal): [1,2,4]triazolo[4,3-a]phthalazines: inhibitors of diverse bromodomains.
Published in: J Med Chem

Ligand: CBPD-409 (Synthetic organic)
Interaction type: None
Action: Binding
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Discovery of CBPD-409 as a Highly Potent, Selective, and Orally Efficacious CBP/p300 PROTAC Degrader for the Treatment of Advanced Prostate Cancer.
Published in: J Med Chem

Ligand: CBPD-268 (Synthetic organic)
Interaction type: None
Action: Binding
Ligand approved: no
Primary target: no
Median affinity: 7.960000038146973 pIC50
Reference (Journal): Discovery of CBPD-268 as an Exceptionally Potent and Orally Efficacious CBP/p300 PROTAC Degrader Capable of Achieving Tumor Regression.
Published in: J Med Chem
Target family: Non-enzymatic BRD containing proteins (type: other_protein)
Target: CECR2 histone acetyl-lysine reader

Ligand: NVS-1 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity:  pIC50
Reference (Webpage): NVS-CECR2-1 A chemical probe for CECR2

Ligand: compound 50 [PMID: 24313754] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.800000190734863 pIC50
Reference (Journal): [1,2,4]triazolo[4,3-a]phthalazines: inhibitors of diverse bromodomains.
Published in: J Med Chem
Target family: Non-enzymatic BRD containing proteins (type: other_protein)
Target: bromodomain testis associated

Ligand: XD14 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 5.920000076293945 pKd
Reference (Journal): 4-Acyl pyrroles: mimicking acetylated lysines in histone code reading.
Published in: Angew Chem Int Ed Engl

Ligand: WNY0824 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.510000228881836 pIC50
Reference (Journal): Design, synthesis, and biological evaluation of 4,5-dihydro-[1,2,4]triazolo[4,3-f]pteridine derivatives as novel dual-PLK1/BRD4 inhibitors.
Published in: Eur J Med Chem
Target family: Non-enzymatic BRD containing proteins (type: other_protein)
Target: bromodomain and PHD finger containing 1

Ligand: PFI-4 (Synthetic organic)
Interaction type: None
Action: Binding
Ligand approved: no
Primary target: yes
Median affinity: 7.889999866485596 pKd
Reference (Webpage): PFI-4 A chemical probe for BRPF1B.
Target family: Non-enzymatic BRD containing proteins (type: other_protein)
Target: bromodomain and PHD finger containing 3

Ligand: NI-57 (Synthetic organic)
Interaction type: None
Action: Binding
Ligand approved: no
Primary target: no
Median affinity: 6.389999866485596 pKd
Reference (Webpage): NI-57 – a chemical probe for BRPF bromodomains.

Ligand: OF-1 (Synthetic organic)
Interaction type: None
Action: Binding
Ligand approved: no
Primary target: no
Median affinity: 5.619999885559082 pKd
Reference (Webpage): OF-1 A chemical probe for BRPF bromodomains
Target family: Non-enzymatic BRD containing proteins (type: other_protein)
Target: bromodomain PHD finger transcription factor

Ligand: MS363 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 5.789999961853027 pKi
Reference (Journal): Structure-guided design of potent diazobenzene inhibitors for the BET bromodomains.
Published in: J Med Chem
Target family: Non-enzymatic BRD containing proteins (type: other_protein)
Target: bromodomain testis associated

Ligand: GSK852 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.800000190734863 pKd
Reference (Journal): Optimization of a Series of 2,3-Dihydrobenzofurans as Highly Potent, Second Bromodomain (BD2)-Selective, Bromo and Extra-Terminal Domain (BET) Inhibitors.
Published in: J Med Chem

Ligand: GSK852 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 4.800000190734863 pKd
Reference (Journal): Optimization of a Series of 2,3-Dihydrobenzofurans as Highly Potent, Second Bromodomain (BD2)-Selective, Bromo and Extra-Terminal Domain (BET) Inhibitors.
Published in: J Med Chem

Ligand: (+)-JQ1 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8 pIC50
Reference (Journal): Small-molecule inhibition of BRDT for male contraception.
Published in: Cell

Ligand: (+)-JQ1 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.960000038146973 pIC50
Reference (Journal): Small-molecule inhibition of BRDT for male contraception.
Published in: Cell
Target family: Non-enzymatic BRD containing proteins (type: other_protein)
Target: bromodomain adjacent to zinc finger domain 2A

Ligand: BAZ2-ICR (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 6.960000038146973 pKd
Reference (Journal): Structure Enabled Design of BAZ2-ICR, A Chemical Probe Targeting the Bromodomains of BAZ2A and BAZ2B.
Published in: J Med Chem

Ligand: GSK2801 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 6.590000152587891 pKd
Reference (Webpage): GSK2801: A Selective Chemical Probe for BAZ2B/A bromodomains.
Target family: Non-enzymatic BRD containing proteins (type: other_protein)
Target: bromodomain adjacent to zinc finger domain 2B

Ligand: BAZ2-ICR (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.769999980926514 pKd
Reference (Journal): Structure Enabled Design of BAZ2-ICR, A Chemical Probe Targeting the Bromodomains of BAZ2A and BAZ2B.
Published in: J Med Chem

Ligand: compound 1 [PMID: 25719566] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 4.599999904632568 pIC50
Reference (Journal): Structure Enabled Design of BAZ2-ICR, A Chemical Probe Targeting the Bromodomains of BAZ2A and BAZ2B.
Published in: J Med Chem

Ligand: compound 7 [PMID: 25719566] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 5.960000038146973 pIC50
Reference (Journal): Structure Enabled Design of BAZ2-ICR, A Chemical Probe Targeting the Bromodomains of BAZ2A and BAZ2B.
Published in: J Med Chem

Ligand: GSK2801 (Synthetic organic)
Interaction type: Inhibitor
Action: Binding
Ligand approved: no
Primary target: yes
Median affinity: 6.869999885559082 pKd
Reference (Webpage): GSK2801: A Selective Chemical Probe for BAZ2B/A bromodomains.
Target family: Non-enzymatic BRD containing proteins (type: other_protein)
Target: bromodomain and PHD finger containing 1

Ligand: compound 1 [PMID: 25408830] (Synthetic organic)
Interaction type: None
Action: Binding
Ligand approved: no
Primary target: yes
Median affinity: 5 pIC50
Reference (Journal): 1,3-Dimethyl Benzimidazolones Are Potent, Selective Inhibitors of the BRPF1 Bromodomain.
Published in: ACS Med Chem Lett

Ligand: compound 2 [PMID: 25408830] (Synthetic organic)
Interaction type: None
Action: Binding
Ligand approved: no
Primary target: yes
Median affinity: 5.599999904632568 pIC50
Reference (Journal): 1,3-Dimethyl Benzimidazolones Are Potent, Selective Inhibitors of the BRPF1 Bromodomain.
Published in: ACS Med Chem Lett

Ligand: compound 34 [PMID: 25974391] (Synthetic organic)
Interaction type: None
Action: Binding
Ligand approved: no
Primary target: yes
Median affinity: 6.860000133514404 pKd
Reference (Journal): Discovery of a Chemical Tool Inhibitor Targeting the Bromodomains of TRIM24 and BRPF.
Published in: J Med Chem

Ligand: compound 3 [PMID: 25408830] (Synthetic organic)
Interaction type: None
Action: Binding
Ligand approved: no
Primary target: yes
Median affinity: 4.300000190734863 pIC50
Reference (Journal): 1,3-Dimethyl Benzimidazolones Are Potent, Selective Inhibitors of the BRPF1 Bromodomain.
Published in: ACS Med Chem Lett

Ligand: NI-57 (Synthetic organic)
Interaction type: None
Action: Binding
Ligand approved: no
Primary target: yes
Median affinity: 7.510000228881836 pKd
Reference (Webpage): NI-57 – a chemical probe for BRPF bromodomains.

Ligand: OF-1 (Synthetic organic)
Interaction type: None
Action: Binding
Ligand approved: no
Primary target: no
Median affinity: 7 pKd
Reference (Webpage): OF-1 A chemical probe for BRPF bromodomains
Target family: Non-enzymatic BRD containing proteins (type: other_protein)
Target: E1A binding protein p300

Ligand: I-CBP112 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.199999809265137 pKd
Reference (Webpage): I-CBP112 A CREBBP/EP300-selective chemical probe

Ligand: H3-CoA-20 (Peptide)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 3.700000047683716 pIC50
Reference (Journal): HATs off: selective synthetic inhibitors of the histone acetyltransferases p300 and PCAF.
Published in: Mol Cell

Ligand: garcinol (Natural product)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 5.150000095367432 pIC50
Reference (Journal): Polyisoprenylated benzophenone, garcinol, a natural histone acetyltransferase inhibitor, represses chromatin transcription and alters global gene expression.
Published in: J Biol Chem

Ligand: epigallocatechin-3-gallate (Natural product)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 4.519999980926514 pIC50
Reference (Journal): Epigallocatechin-3-gallate, a histone acetyltransferase inhibitor, inhibits EBV-induced B lymphocyte transformation via suppression of RelA acetylation.
Published in: Cancer Res

Ligand: curcumin (Natural product)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 4.599999904632568 pIC50
Reference (Journal): Curcumin, a novel p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription.
Published in: J Biol Chem

Ligand: CBPD-409 (Synthetic organic)
Interaction type: None
Action: Binding
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Discovery of CBPD-409 as a Highly Potent, Selective, and Orally Efficacious CBP/p300 PROTAC Degrader for the Treatment of Advanced Prostate Cancer.
Published in: J Med Chem

Ligand: CBPD-268 (Synthetic organic)
Interaction type: None
Action: Binding
Ligand approved: no
Primary target: no
Median affinity: 8.020000457763672 pIC50
Reference (Journal): Discovery of CBPD-268 as an Exceptionally Potent and Orally Efficacious CBP/p300 PROTAC Degrader Capable of Achieving Tumor Regression.
Published in: J Med Chem

Ligand: C646 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.400000095367432 pKi
Reference (Journal): Virtual ligand screening of the p300/CBP histone acetyltransferase: identification of a selective small molecule inhibitor.
Published in: Chem Biol

Ligand: anacardic acid (Natural product)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 5.300000190734863 pIC50
Reference (Journal): Small molecule modulators of histone acetyltransferase p300.
Published in: J Biol Chem
Target family: Non-enzymatic BRD containing proteins (type: other_protein)
Target: CREB binding protein

Ligand: SGC-CBP30 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 7.159999847412109 pIC50
Reference (Journal): Bromodomains and their pharmacological inhibitors.
Published in: ChemMedChem
Target family: Non-enzymatic BRD containing proteins (type: other_protein)
Target: SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4

Ligand: SMD-3040 (Synthetic organic)
Interaction type: None
Action: Binding
Ligand approved: no
Primary target: no
Median affinity: 7.889999866485596 pKd
Reference (Journal): Discovery of SMD-3040 as a Potent and Selective SMARCA2 PROTAC Degrader with Strong <i>in vivo</i> Antitumor Activity.
Published in: J Med Chem

Ligand: PFI-3 (Synthetic organic)
Interaction type: Inhibitor
Action: Binding
Ligand approved: no
Primary target: yes
Median affinity: 7.050000190734863 pKd
Reference (Webpage): PFI-3 A Selective chemical probe for SMARCA bromodomains.

Ligand: GNE-064 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.460000038146973 pIC50
Reference (Journal): GNE-064: A Potent, Selective, and Orally Bioavailable Chemical Probe for the Bromodomains of SMARCA2 and SMARCA4 and the Fifth Bromodomain of PBRM1.
Published in: J Med Chem

Ligand: GNE-064 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8 pIC50
Reference (Journal): GNE-064: A Potent, Selective, and Orally Bioavailable Chemical Probe for the Bromodomains of SMARCA2 and SMARCA4 and the Fifth Bromodomain of PBRM1.
Published in: J Med Chem

Ligand: A947 (Synthetic organic)
Interaction type: None
Action: Binding
Ligand approved: no
Primary target: no
Median affinity: 7.190000057220459 pKd
Reference (Journal): Selective PROTAC-mediated degradation of SMARCA2 is efficacious in SMARCA4 mutant cancers.
Published in: Nat Commun